| Dr James E Ewing, MD | |
|
105 Greenbriar Dr, Suite A, Campbellsville, KY 42718-9615 | |
| (270) 465-3595 | |
| (270) 789-2044 |
| Full Name | Dr James E Ewing |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 32 Years |
| Location | 105 Greenbriar Dr, Campbellsville, Kentucky |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376532564 | NPI | - | NPPES |
| 65931966 | Medicaid | KY | |
| CG2235 | Other | KY | RAILROAD MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 29697 (Kentucky) | Primary |
| 207Q00000X | Family Medicine | 29697 (Kentucky) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Taylor Regional Hospital | Campbellsville, KY | Hospital |
| Jane Todd Crawford Hospital | Greensburg, KY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Taylor Regional Medical Group,llc | 4880616622 | 47 |
News Archive
Cortical hyperexcitability is an intrinsic feature of amyotrophic lateral sclerosis symptoms in patients carrying the chromosome 9 open reading frame 72 gene hexanucleotide repeat expansion, show study findings.
"U.S. government officials say they expect to put the finishing touches this month on new rules designed to help funding agencies identify and regulate especially problematic H5N1 studies before they begin," which would allow influenza researchers "to lift a year-old, self-imposed moratorium on certain kinds of potentially dangerous experiments," Science reports.
Living cells are surrounded by a membrane that tightly regulates what gets in and out of the cell. This barrier is necessary for cells to control their internal environment, but it makes it more difficult for scientists to deliver large molecules such as nanoparticles for imaging, or proteins that can reprogram them into pluripotent stem cells.
Cornerstone Pharmaceuticals, Inc., a clinical stage company and leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of a Phase I clinical trial assessing the safety and efficacy of escalating doses of CPI-613, in combination with bendamustine and rituximab, in patients with relapsed or refractory B-cell Non-Hodgkin lymphoma (NHL).
› Verified 6 days ago
| Entity Name | Taylor Regional Medical Group,llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174697601 PECOS PAC ID: 4880616622 Enrollment ID: O20051221000527 |
News Archive
Cortical hyperexcitability is an intrinsic feature of amyotrophic lateral sclerosis symptoms in patients carrying the chromosome 9 open reading frame 72 gene hexanucleotide repeat expansion, show study findings.
"U.S. government officials say they expect to put the finishing touches this month on new rules designed to help funding agencies identify and regulate especially problematic H5N1 studies before they begin," which would allow influenza researchers "to lift a year-old, self-imposed moratorium on certain kinds of potentially dangerous experiments," Science reports.
Living cells are surrounded by a membrane that tightly regulates what gets in and out of the cell. This barrier is necessary for cells to control their internal environment, but it makes it more difficult for scientists to deliver large molecules such as nanoparticles for imaging, or proteins that can reprogram them into pluripotent stem cells.
Cornerstone Pharmaceuticals, Inc., a clinical stage company and leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of a Phase I clinical trial assessing the safety and efficacy of escalating doses of CPI-613, in combination with bendamustine and rituximab, in patients with relapsed or refractory B-cell Non-Hodgkin lymphoma (NHL).
› Verified 6 days ago
| Entity Name | Taylor Regional Medical Group,llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699030031 PECOS PAC ID: 4880616622 Enrollment ID: O20120827000184 |
News Archive
Cortical hyperexcitability is an intrinsic feature of amyotrophic lateral sclerosis symptoms in patients carrying the chromosome 9 open reading frame 72 gene hexanucleotide repeat expansion, show study findings.
"U.S. government officials say they expect to put the finishing touches this month on new rules designed to help funding agencies identify and regulate especially problematic H5N1 studies before they begin," which would allow influenza researchers "to lift a year-old, self-imposed moratorium on certain kinds of potentially dangerous experiments," Science reports.
Living cells are surrounded by a membrane that tightly regulates what gets in and out of the cell. This barrier is necessary for cells to control their internal environment, but it makes it more difficult for scientists to deliver large molecules such as nanoparticles for imaging, or proteins that can reprogram them into pluripotent stem cells.
Cornerstone Pharmaceuticals, Inc., a clinical stage company and leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of a Phase I clinical trial assessing the safety and efficacy of escalating doses of CPI-613, in combination with bendamustine and rituximab, in patients with relapsed or refractory B-cell Non-Hodgkin lymphoma (NHL).
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr James E Ewing, MD 105 Greenbriar Dr, Suite A, Campbellsville, KY 42718-9615 Ph: (270) 465-3595 | Dr James E Ewing, MD 105 Greenbriar Dr, Suite A, Campbellsville, KY 42718-9615 Ph: (270) 465-3595 |
News Archive
Cortical hyperexcitability is an intrinsic feature of amyotrophic lateral sclerosis symptoms in patients carrying the chromosome 9 open reading frame 72 gene hexanucleotide repeat expansion, show study findings.
"U.S. government officials say they expect to put the finishing touches this month on new rules designed to help funding agencies identify and regulate especially problematic H5N1 studies before they begin," which would allow influenza researchers "to lift a year-old, self-imposed moratorium on certain kinds of potentially dangerous experiments," Science reports.
Living cells are surrounded by a membrane that tightly regulates what gets in and out of the cell. This barrier is necessary for cells to control their internal environment, but it makes it more difficult for scientists to deliver large molecules such as nanoparticles for imaging, or proteins that can reprogram them into pluripotent stem cells.
Cornerstone Pharmaceuticals, Inc., a clinical stage company and leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of a Phase I clinical trial assessing the safety and efficacy of escalating doses of CPI-613, in combination with bendamustine and rituximab, in patients with relapsed or refractory B-cell Non-Hodgkin lymphoma (NHL).
› Verified 6 days ago
James A Ewing, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 105 Greenbriar Dr, Suite A, Campbellsville, KY 42718 Phone: 270-465-3595 Fax: 270-789-2044 |